AKT1 and neoplasm: Src can increase pro-inflammatory cytokines production for tumor development and activate survival effectors for chemoresistance (Su et al., 2014; Tsai et al., 2017), including TNF-α, IL-1β, IL6, phosphoinositide 3-kinases (PI3Ks), AKT and STAT3.